147 related articles for article (PubMed ID: 35718333)
21. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
22. Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.
Chai D; Yue Y; Xu W; Dong C; Xiong S
Hum Vaccin Immunother; 2014; 10(5):1284-94. PubMed ID: 24614684
[TBL] [Abstract][Full Text] [Related]
23. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.
Knowlton KU; Jeon ES; Berkley N; Wessely R; Huber S
J Virol; 1996 Nov; 70(11):7811-8. PubMed ID: 8892902
[TBL] [Abstract][Full Text] [Related]
24. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
[TBL] [Abstract][Full Text] [Related]
25. Role of RNA Domain Structure and Orientation in the Coxsackievirus B3 Virulence Phenotype.
Phillips L; Tapprich WE
J Virol; 2023 May; 97(5):e0044823. PubMed ID: 37074194
[TBL] [Abstract][Full Text] [Related]
26. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes.
Yun SH; Shin HH; Ju ES; Lee YJ; Lim BK; Jeon ES
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344926
[TBL] [Abstract][Full Text] [Related]
28. α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.
Wu CY; Feng Y; Qian GC; Wu JH; Luo J; Wang Y; Chen GJ; Guo XK; Wang ZJ
Clin Exp Immunol; 2010 Oct; 162(1):178-87. PubMed ID: 20726989
[TBL] [Abstract][Full Text] [Related]
29. A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice.
Chapman NM; Ragland A; Leser JS; Höfling K; Willian S; Semler BL; Tracy S
J Virol; 2000 May; 74(9):4047-56. PubMed ID: 10756016
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
31. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
32. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
33. MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells.
Pryshliak M; Hazini A; Knoch K; Dieringer B; Tolksdorf B; Solimena M; Kurreck J; Pinkert S; Fechner H
FEBS Lett; 2020 Feb; 594(4):763-775. PubMed ID: 31643074
[TBL] [Abstract][Full Text] [Related]
34. Recombinant Mouse β-Defensin 3 Protects against Coxsackievirus B3-Induced Myocarditis in Mice.
Jiang Y; Zhu R; Luo L; Mu Q; Zhu Y; Luo H; Zou X; Shen X
Intervirology; 2015; 58(6):343-9. PubMed ID: 26829552
[TBL] [Abstract][Full Text] [Related]
35. Coxsackievirus B3 infects and disrupts human induced-pluripotent stem cell derived brain-like endothelial cells.
Mamana J; Humber GM; Espinal ER; Seo S; Vollmuth N; Sin J; Kim BJ
Front Cell Infect Microbiol; 2023; 13():1171275. PubMed ID: 37139492
[TBL] [Abstract][Full Text] [Related]
36. M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine.
Ye T; Yue Y; Fan X; Dong C; Xu W; Xiong S
Vaccine; 2014 Jul; 32(35):4457-4465. PubMed ID: 24958702
[TBL] [Abstract][Full Text] [Related]
37. Colchicine aggravates coxsackievirus B3 infection in mice.
Smilde BJ; Woudstra L; Fong Hing G; Wouters D; Zeerleder S; Murk JL; van Ham M; Heymans S; Juffermans LJ; van Rossum AC; Niessen HW; Krijnen PA; Emmens RW
Int J Cardiol; 2016 Aug; 216():58-65. PubMed ID: 27140338
[TBL] [Abstract][Full Text] [Related]
38. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
Wang M; Yue Y; Dong C; Li X; Xu W; Xiong S
Clin Vaccine Immunol; 2013 Nov; 20(11):1743-51. PubMed ID: 24027262
[TBL] [Abstract][Full Text] [Related]
39. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication.
Wessely R; Klingel K; Knowlton KU; Kandolf R
Circulation; 2001 Feb; 103(5):756-61. PubMed ID: 11156890
[TBL] [Abstract][Full Text] [Related]
40. [The suppressive effect of MiR-490 on coxsackievirus B3 replication].
Wang LL; Zhong ZH; Wang Q; Lu P; Li M; Xu HY
Bing Du Xue Bao; 2014 Nov; 30(6):619-23. PubMed ID: 25868275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
